Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Meloxicam and 5′-Carboxymeloxicam in Oral Fluid Samples
暂无分享,去创建一个
A. M. Calvo | G. M. Oliveira | B. L. Colombini-Ishikiriama | Flavio Augusto Cardoso Faria | Viviane Silva Siqueira-Sandrin | Carlos Ferreira Santos | Leticia Alves de Lima Ferrari | T. Dionísio
[1] T. J. Dionísio,et al. Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazol—Results , 2022, PloS one.
[2] T. J. Dionísio,et al. CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid , 2022, Metabolites.
[3] T. J. Dionísio,et al. Detection and quantification of prostaglandin E2 in saliva by liquid chromatography-tandem mass spectrometry using microextraction by packed sorbent. , 2022, Prostaglandins & other lipid mediators.
[4] A. M. Calvo,et al. Analysis of Different Methods of Extracting NSAIDs in Biological Fluid Samples for LC-MS/MS Assays: Scoping Review , 2022, Metabolites.
[5] C. Jang,et al. Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes , 2021, Archives of Pharmacal Research.
[6] Rongfeng Hu,et al. Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. , 2021, Biomedical chromatography : BMC.
[7] M. Whirl‐Carrillo,et al. An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine , 2021, Clinical pharmacology and therapeutics.
[8] C. Jang,et al. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism , 2021, Archives of Pharmacal Research.
[9] T. J. Dionísio,et al. Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography–tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole , 2020, PloS one.
[10] S. Armenta,et al. Determination of Third Generation Synthetic Cannabinoids in Oral Fluids. , 2020, Journal of analytical toxicology.
[11] Huixi Zou,et al. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges , 2020, Frontiers in Pharmacology.
[12] R. Lucena,et al. Microextraction approaches for bioanalytical applications: An overview. , 2019, Journal of chromatography. A.
[13] Shemille A. Collingwood,et al. Meloxicam in the management of post-operative pain: Narrative review , 2018, Journal of anaesthesiology, clinical pharmacology.
[14] Dongmei Li,et al. Facile derivatization of ultratrace carboxylic acids in saliva for quantification by HPLC–MS/MS , 2018, Analytical and Bioanalytical Chemistry.
[15] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[16] V. Samanidou,et al. Green approaches in sample preparation of bioanalytical samples prior to chromatographic analysis. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[17] Sook-Joung Lee,et al. Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen , 2017, Drug design, development and therapy.
[18] Xiaomei Zhuang,et al. PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.
[19] V. Lanchote,et al. Effective method for the detection of piroxicam in human plasma using HPLC. , 2016, Brazilian oral research.
[20] K. Srisailam,et al. Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies , 2016, SpringerPlus.
[21] M. H. Fernandes,et al. Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. , 2016, Journal of pharmaceutical and biomedical analysis.
[22] B. Grung,et al. Development and validation of an extraction method for the determination of pro-inflammatory eicosanoids in human plasma using liquid chromatography-tandem mass spectrometry. , 2014, Journal of chromatography. A.
[23] J. Katz. COX-2 inhibition: what we learned--a controversial update on safety data. , 2013, Pain medicine.
[24] M. Abdel-Rehim,et al. Screening and determination of drugs in human saliva utilizing microextraction by packed sorbent and liquid chromatography-tandem mass spectrometry. , 2013, Biomedical chromatography : BMC.
[25] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[26] T. Arafat,et al. Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. , 2012, Molecular pharmaceutics.
[27] T. Toyo’oka,et al. Simple and practical derivatization procedure for enhanced detection of carboxylic acids in liquid chromatography-electrospray ionization-tandem mass spectrometry. , 2010, Journal of pharmaceutical and biomedical analysis.
[28] V. Rollason,et al. Pharmacogenetics of analgesics: toward the individualization of prescription. , 2008, Pharmacogenomics.
[29] C. Jang,et al. Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[30] Xiaoyan Chen,et al. Determination of meloxicam in human plasma by liquid chromatography-tandem mass spectrometry following transdermal administration. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[31] R. Moreno,et al. Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. , 2006, International journal of clinical pharmacology and therapeutics.
[32] L. Blomberg,et al. Microextraction in packed syringe (MEPS) for liquid and gas chromatographic applications. Part II--Determination of ropivacaine and its metabolites in human plasma samples using MEPS with liquid chromatography/tandem mass spectrometry. , 2004, Journal of mass spectrometry : JMS.
[33] E. Rondinelli,et al. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians , 2004, Clinical pharmacology and therapeutics.
[34] T. Ebner,et al. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. , 1999, The Journal of pharmacology and experimental therapeutics.
[35] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[36] D. Türck,et al. A review of the clinical pharmacokinetics of meloxicam. , 1996, British journal of rheumatology.
[37] C. Dollery,et al. Drug concentration in saliva , 1978, Clinical pharmacology and therapeutics.
[38] K. Feller,et al. On the distribution of drugs in saliva and blood plasma. , 1977, International journal of clinical pharmacology and biopharmacy.
[39] P Kellaway,et al. Use of saliva in therapeutic drug monitoring. , 1977, Clinical chemistry.
[40] M. H. Fernandes,et al. Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. , 2021, Brazilian dental journal.
[41] T. Schmidt,et al. Solvent-free microextraction techniques in gas chromatography , 2011, Analytical and Bioanalytical Chemistry.
[42] A. S. Trindade,et al. Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. , 2007, International journal of oral and maxillofacial surgery.
[43] A. Guillouzo,et al. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.